scholarly journals Nursing Skill and Responsibility in Administration of Injection Actilyse

2021 ◽  
pp. 151-155
Author(s):  
Mayur B. Wanjari ◽  
Deeplata Mendhe ◽  
Pratibha Wankhede
Keyword(s):  
Plasminogen Activator ◽  
Recombinant Dna ◽  
Tissue Type ◽  
Sterile Water ◽  
Stroke Patients ◽  
Recombinant Dna Technology ◽  
Type Plasminogen Activator ◽  
Blood Clots ◽  
Tissue Plasminogen ◽  
Heart Blood

Actilyse can break blood clots that form in the heart, blood arteries, or lungs during a heart attack. This medication is also given to stroke patients to improve recovery and reduce the likelihood of impairment. Recombinant DNA technology was used to create Activase, a tissue plasminogen activator. It is a sterile, purified glycoprotein of 527 amino acids. It is made by combining complementary DNA (cDNA) from a human melanoma cell line with the natural human tissue-type plasminogen activator. After reconstitution with Sterile Water for Injection, USP, Activase is a sterile, white to off-white lyophilized powder for intravenous injection.

Increased Yield of Human Tissue-Type Plasminogen Activator Obtained by Means of Recombinant DNA Technology

1985 ◽  
Vol 54 (02) ◽  
pp. 422-424 ◽  
Author(s):  
M J Browne ◽  
I Dodd ◽  
J E Carey ◽  
C G Chapman ◽  
J H Robinson
Keyword(s):  
Cell Line ◽  
Plasminogen Activator ◽  
Human Tissue ◽  
Recombinant Dna ◽  
Sodium Dodecyl ◽  
Tissue Type ◽  
Parent Cell ◽  
Recombinant Dna Technology ◽  
Tissue Type Plasminogen Activator ◽  
Type Plasminogen Activator

SummaryExtra copies of the human tissue-type plasminogen activator (t-PA) gene were introduced into the Bowes melanoma cell line. We obtained a recombinant cell line (TRBM6) which secretes approximately ten-fold more t-PA than the parent cell line. The identity of the plasminogen activator made by the new cell line was confirmed by sizing on sodium dodecyl sulphate polyacrylamide gels and by specific quenching using anti-t-PA antibody. We estimate that the recombinant line produces t-PA at a rate of approximately 3 pg/cell/24 hr and that t-PA accumulates in the harvest medium at a rate of approximately 4000 International t-PA Units/ml/24 hr.

The Stability of Tissue Plasminogen Activator (t-PA)

1983 ◽  
Vol 50 (03) ◽  
pp. 650-651 ◽  
Author(s):  
P J Gaffney ◽  
J Templeman ◽  
A D Curtis ◽  
P J Campbell
Keyword(s):  
Tissue Culture ◽  
Plasminogen Activator ◽  
Melanoma Cell ◽  
Recombinant Dna ◽  
Tissue Type ◽  
Cell Tissue ◽  
Type Plasminogen Activator ◽  
Tissue Plasminogen ◽  
The Stability ◽  
Further Development

SummarySince tissue-type plasminogen activator (t-PA) derived from tissue culture and recombinant DNA procedures has been proposed for use in thrombolytic therapy in man, it is essential that the t-PA molecule should display reasonable stability in a lyophilised state to facilitate its usefulness. In this study, four laboratories compared the potencies of three preparations of t-PA following storage at 4°, 20°, 37° and 45° C, using each t-PA stored at -20° C as a reference (100% activity) in each case. A pig heart extract of t-PA was the most stable, losing no activity when stored for 30 days at 37° C, while two melanoma cell tissue culture extracts varied in their storage behaviour. One was quite stable at 37° C (losing about 3% of its activity) while the other lost about 16%. Thus both the pig heart t-PA and one t-PA from melanoma cell culture proved suitable for the further development of reference standards for t-PA activity.

An Enzyme Linked Immunosorbent Assay for Determination of Tissue Plasminogen Activator Applied to Patients with Thromboembolic Disease

1983 ◽  
Vol 50 (03) ◽  
pp. 740-744 ◽  
Author(s):  
Nils Bergsdorf ◽  
Torbjörn Nilsson ◽  
Per Wallén
Keyword(s):  
Plasminogen Activator ◽  
Tissue Plasminogen Activator ◽  
Specific Activity ◽  
Thromboembolic Disease ◽  
Tissue Type ◽  
Enzyme Linked Immunosorbent Assay ◽  
Type Plasminogen Activator ◽  
Tissue Plasminogen ◽  
Normal Human

SummaryUtilizing the immunoglobulin fraction from a goat antiserum against human uterine tissue plasminogen activator, an enzyme- linked immunoassay for tissue-type plasminogen activator in human plasma has been developed. With the new method, the concentration of t-PA in normal human acidified plasma is found to be 4.0 ± 1.8 (SD) ng/ml. It increases to 12 ng/ml after a tomiquet test, and to 14 ng/ml after strenous physical exercise. In a group of patients with idiopathic thromboembolic disease, the resting t-PA concentration was 5 ng/ml and the post-occlusion value 16 ng/ml. Furthermore, the patients also exhibited a normal post-occlusion rise in the concentration of plasmin-α2-antiplasmin complex. However, in 37% of the post-occlusion patient plasmas, virtually no increase in t-PA could be detected by a specific activity assay. The results indicate that the reason for a defective post-occlusion fibrinolytic activity in a majority of cases may be the presence of increased concentrations of a fast-acting specific t-PA inhibitor.

Abstract TMP19: Intravenous Recombinant Tissue-type Plasminogen Activator Use in Young Adults With Acute Ischemic Stroke

Stroke ◽  
2017 ◽  
Vol 48 (suppl_1) ◽  
Author(s):  
Jodi A Dodds ◽  
Ying Xian ◽  
Shubin Sheng ◽  
Gregg Fonarow ◽  
Ronald A Matsouaka ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Acute Ischemic Stroke ◽  
Plasminogen Activator ◽  
Older Patients ◽  
Young Patients ◽  
Tissue Type ◽  
Stroke Patients ◽  
Younger Patients ◽  
Tissue Type Plasminogen Activator ◽  
Type Plasminogen Activator

Background: Intravenous recombinant tissue-type plasminogen activator (rt-PA) administration improves outcomes in acute ischemic stroke. However, young patients (<40 years old) presenting with stroke symptoms may experience delays in treatment due to misdiagnosis or a reluctance to treat since they do not fit the profile of a typical stroke patient. Methods: We analyzed data from the large national Get With The Guidelines–Stroke registry for acute ischemic stroke patients hospitalized between January 2009 and September 2015. Multivariable models with generalized estimating equations (GEE) were used to test for differences between younger (age 18-40) and older (age > 40) acute ischemic stroke patients, controlling for patient and hospital characteristics including stroke severity. Results: Of 1,320,965 AIS patients admitted to participating hospitals, 2.3% (30,448) were aged 18-40. Among these patients, 12.5% received rt-PA versus 8.8% of those aged >40 (p<0.001). Of patients arriving within 3.5 hours of symptom onset without contraindications, 68.7% of younger patients received IV rt-PA versus 63.3% of older patients (adjusted OR [aOR] 1.30, 95% CI 1.21 to 1.40), without evidence that age-related differences varied by sex (interaction p-value 0.25). Odds ratios of achieving target door-to-CT times and door-to-needle (DTN) times, and outcomes of rtPA-treated patients, are shown in the Table. Conclusions: Young acute ischemic stroke patients did not receive rt-PA treatment at lower rates than older patients. Outcomes were better and the rate of symptomatic intracranial hemorrhage was lower in the young patients. However, younger patients had significantly longer door-to-CT and DTN times, providing an opportunity to improve the care of these patients.

scholarly journals Intravenous Tissue-Type Plasminogen Activator in Acute Ischemic Stroke Patients With History of Stroke Plus Diabetes Mellitus

Stroke ◽  
2019 ◽  
Vol 50 (6) ◽  
pp. 1497-1503 ◽  
Author(s):  
Matthew E. Ehrlich ◽  
Li Liang ◽  
Haolin Xu ◽  
Andrzej S. Kosinski ◽  
Adrian F. Hernandez ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Ischemic Stroke ◽  
Acute Ischemic Stroke ◽  
Plasminogen Activator ◽  
Tissue Type ◽  
Stroke Patients ◽  
Tissue Type Plasminogen Activator ◽  
Type Plasminogen Activator ◽  
History Of

scholarly journals The interplay between tissue plasminogen activator domains and fibrin structures in the regulation of fibrinolysis: kinetic and microscopic studies

Blood ◽  
2011 ◽  
Vol 117 (2) ◽  
pp. 661-668 ◽  
Author(s):  
Colin Longstaff ◽  
Craig Thelwell ◽  
Stella C. Williams ◽  
Marta M. C. G. Silva ◽  
László Szabó ◽  
...  
Keyword(s):  
Green Fluorescent Protein ◽  
Plasminogen Activator ◽  
Fluorescent Protein ◽  
Tissue Type ◽  
Plasminogen Activation ◽  
Fine Mesh ◽  
Type Plasminogen Activator ◽  
Tissue Plasminogen ◽  
Microscopic Studies ◽  
Green Fluorescent

AbstractRegulation of tissue-type plasminogen activator (tPA) depends on fibrin binding and fibrin structure. tPA structure/function relationships were investigated in fibrin formed by high or low thrombin concentrations to produce a fine mesh and small pores, or thick fibers and coarse structure, respectively. Kinetics studies were performed to investigate plasminogen activation and fibrinolysis in the 2 types of fibrin, using wild-type tPA (F-G-K1-K2-P, F and K2 binding), K1K1-tPA (F-G-K1-K1-P, F binding), and delF-tPA (G-K1-K2-P, K2 binding). There was a trend of enzyme potency of tPA > K1K1-tPA > delF-tPA, highlighting the importance of the finger domain in regulating activity, but the differences were less apparent in fine fibrin. Fine fibrin was a better surface for plasminogen activation but more resistant to lysis. Scanning electron and confocal microscopy using orange fluorescent fibrin with green fluorescent protein-labeled tPA variants showed that tPA was strongly associated with agglomerates in coarse but not in fine fibrin. In later lytic stages, delF-tPA-green fluorescent protein diffused more rapidly through fibrin in contrast to full-length tPA, highlighting the importance of finger domain-agglomerate interactions. Thus, the regulation of fibrinolysis depends on the starting nature of fibrin fibers and complex dynamic interaction between tPA and fibrin structures that vary over time.

Sign in / Sign up

Export Citation Format

Share Document